Astec LifeSciences Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017
January 31, 2018 at 05:59 am EST
Share
Astec LifeSciences Limited reported unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, on standalone basis, the company reported total income from operations of INR 742.850 million compared to INR 623.792 million a year ago. Profit before exceptional items and tax was INR 88.907 million compared to INR 74.333 million a year ago. Profit before tax was INR 130.428 million compared to INR 44.534 million a year ago. Net profit for the period was INR 71.824 million or INR 3.67 per diluted share compared to INR 7.006 million or INR 0.36 per diluted share a year ago.
For the nine months, on standalone basis, the company reported total income from operations of INR 2,424.843 million compared to INR 2,223.001 million a year ago. Profit before exceptional items and tax was INR 249.163 million compared to INR 290.470 million a year ago. Profit before tax was INR 290.684 million compared to INR 244.767 million a year ago. Net profit for the period was INR 178.729 million or INR 9.13 per diluted share compared to INR 156.020 million or INR 7.99 per diluted share a year ago.
For the quarter, on consolidated basis, the company reported total income from operations of INR 742.850 million compared to INR 623.850 million a year ago. Profit before exceptional items and tax was INR 88.439 million compared to INR 74.496 million a year ago. Profit before tax was INR 129.960 million compared to INR 44.697 million a year ago. Net profit for the period was INR 71.485 million compared to INR 7.096 million a year ago. Net profit attributable to owners was INR 71.607 million or INR 3.66 per diluted share compared to INR 7.081 million or INR 0.36 per diluted share a year ago.
For the nine months, on consolidated basis, the company reported total income from operations of INR 2,424.843 million compared to INR 2,229.010 million a year ago. Profit before exceptional items and tax was INR 248.957 million compared to INR 291.879 million a year ago. Profit before tax was INR 290.478 million compared to INR 246.176 million a year ago. Net profit for the period was INR 178.504 million compared to INR 157.180 million a year ago. Net profit attributable to owners was INR 177.470 million or INR 9.07 per diluted share compared to INR 156.572 million or INR 8.01 per diluted share a year ago.
Astec LifeSciences Limited is an India-based company that is primarily engaged in manufacturing a range of agrochemical active ingredients and pharmaceutical intermediates. The Company operates through the Agrochemicals segment. It manufactures a range of fungicides, insecticides, herbicides, and intermediates for its global customers. The Companyâs products and intermediates includes triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, silane derivatives, fluorinated aromatic, aliphatic and heterocyclic intermediates, fluorinated aromatic amines, fluorinated pyridine derivatives, fluorinated aromatic carboxylic acids, fluorinated benzyl alcohols, fluorinated ketones and benzophenones, fluorinated heterocyclic mercaptans, heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, thorium salts, pyrazaloneâs and heterocyclic sulfonyl chlorides.
Astec LifeSciences Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017
ASTEC LIFESCIENCES LIMITED 
